相关实验视频

Updated: Jul 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

根据免疫疗法和化疗相关的 lncRNAs 来分组丸生殖细胞瘤

Jian Cao¹, Zhizhong Liu¹, Junbin Yuan²

¹Hunan Cancer Hospital, Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine of Central South University, Changsha, 410013, Hunan, China.

|February 1, 2024

概括

丸生殖细胞瘤 (TGCT) 可以根据长非编码RNA表达被分为三个亚型. 这种分层有助于预测化学疗法敏感性和潜在的免疫疗法益处,用于精确的TGCT治疗.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
分子生物学分子生物学

背景情况:

丸生殖细胞瘤 (TGCT) 是年轻人中最常见的男性生殖癌症.
像LINC00313,TTY14和RFPL3S这样的长非编码RNA (lncRNAs) 已涉及到TGCT的发展.
基于lncRNA和免疫特征的TGCT分组可以指导精确的治疗策略.

研究的目的:

使用共识集群开发TGCT的预后模型.
根据差异表达的 lncRNAs 来识别不同的TGCT亚型.
为了将这些亚型与治疗反应和免疫特征相关联.

主要方法:

利用了来自癌症基因组图谱 (TCGA) 数据库的TGCT转录组数据.
进行共识聚类分析以分层TGCT患者.
分析了差异表达基因 (DEG) 和免疫学特征.

主要成果:

根据lncRNA表达形状,确定了三种TGCT亚型 (C1,C2,C3).
亚型C1对化疗表现出敏感性.
亚型C2对化疗有抗性,而亚型C3可能受益于免疫疗法.

结论:

已确定的TGCT亚型,定义为表皮进展 (C1),介质细胞进展 (C2) 和T细胞激活 (C3),为个性化治疗提供了一个框架.
根据lncRNA表达和免疫特征分组TGCT对于有效的治疗决策至关重要.

关键词:

化疗化疗是一种化学疗法.分类分类分类分类.免疫治疗是一种免疫疗法.精确的处理精确的处理丸的生殖细胞瘤在ncRNA中,我们可以

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...